Regulatory non-compliance of parallel imported medicines in Kenya and implications for public health: Evidence from Nairobi County.

BACKGROUND

Parallel importation (PI) is a TRIPS-recognized flexibility intended to improve access to medicines through price competition. In low- and middle-income countries, however, concerns persist regarding regulatory oversight, product quality, and patient safety. Empirical evidence on the real-world implementation of PI in Kenya remains limited.

OBJECTIVES

This study aimed to assess the regulatory compliance of selected parallel imported medicines marketed in Nairobi County, identify predictors of compliance, evaluate their market prevalence, and examine whether PI delivers the intended economic benefits for patients.

METHODS

Twenty-two medicines identified as parallel imports were evaluated against Kenyan regulatory requirements, including Pharmacy and Poisons Board (PPB) guidelines on labeling, packaging, patient information leaflets, storage conditions, and the Parallel Imported Medicinal Substances Rules (2019). A mystery-shopper survey covering 2348 retail pharmaceutical outlets across all 85 Nairobi wards estimated the prevalence of non-compliant PI products. Logistic regression was used to identify predictors of compliance, and independent t-tests compared retail prices of PI products with those supplied through authorized channels.

RESULTS

Regulatory non-compliance was widespread. Ninety percent of PI products failed to meet labeling and package insert requirements, primarily due to foreign-language packaging that precluded verification of critical safety information. Forty-five percent displayed storage instructions inconsistent with Kenya's ICH climatic Zone IV requirements, indicating supply chains not adapted to tropical conditions. Overall, 90% of products violated key provisions of the PPB PI Rules. Nearly all PI medicines were off-patent and already had multiple generic alternatives registered in Kenya, undermining the TRIPS-based public health rationale for PI. Unauthorized PI products were identified in approximately 90% of surveyed outlets. Price analysis showed significant differences in 53% of comparisons, but nearly half of PI products offered no economic advantage over authorized equivalents.

CONCLUSIONS

Parallel importation of medicines in Nairobi is characterized by extensive regulatory non-compliance, limited or absent price benefits, and significant risks to medicine quality and patient safety. In its current implementation, PI in Kenya operates largely outside its intended TRIPS scope and fails to deliver meaningful public health value. Strengthened regulatory enforcement, climate-appropriate packaging, mandatory language compliance, and a reassessment of PI policy are urgently required to protect patients and preserve trust in the pharmaceutical system.